{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-VH7S9AL8/338c53bd-9af3-4fa0-bde0-868f802dcacd/PDF","dcterms:extent":"828 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-VH7S9AL8/8be672d7-6a76-4096-afb4-36a75a636786/TEXT","dcterms:extent":"22 KB"}],"edm:TimeSpan":{"@rdf:about":"1992-2026","edm:begin":{"@xml:lang":"en","#text":"1992"},"edm:end":{"@xml:lang":"en","#text":"2026"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-VH7S9AL8","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-FNIFVE9S"},{"@xml:lang":"sl","#text":"Radiology and oncology (Ljubljana)"}],"dcterms:issued":"2026","dc:creator":["Arko, Rozala","Gašljević, Gorana","Hribernik, Nežka","Reberšek, Martina"],"dc:format":[{"@xml:lang":"sl","#text":"številka:2"},{"@xml:lang":"sl","#text":"letnik:60"},{"@xml:lang":"sl","#text":"str. 288-293"}],"dc:identifier":["DOI:10.2478/raon-2026-0020","ISSN:1318-2099","COBISSID_HOST:275560707","URN:URN:NBN:SI:doc-VH7S9AL8"],"dc:language":"en","dc:publisher":[{"@xml:lang":"sl","#text":"Croatian Medical Association - Croatian Society of Radiology"},{"@xml:lang":"sl","#text":"Slovenian Medical Society - Section of Radiology"}],"dc:subject":[{"@xml:lang":"en","#text":"adjuvant immunotherapy"},{"@xml:lang":"sl","#text":"adjuvantna imunoterapija"},{"@xml:lang":"en","#text":"gastroesophageal junction cancer"},{"@xml:lang":"sl","#text":"nivolumab"},{"@xml:lang":"en","#text":"oesophageal cancer"},{"@xml:lang":"sl","#text":"rak gastroezofagealnega prehoda"},{"@xml:lang":"sl","#text":"rak požiralnika"}],"dcterms:temporal":{"@rdf:resource":"1992-2026"},"dc:title":{"@xml:lang":"sl","#text":"Adjuvant nivolumab in resected oesophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy| Slovenian real-world data|"},"dc:description":{"@xml:lang":"sl","#text":"Adjuvant nivolumab has become the new standard of care for patients with oesophageal and gastroesophageal junction cancer (OEC/GEJC) following neoadjuvant chemoradiotherapy (neoCRT) and surgical resection. In Slovenia, this treatment has been in use since January 2022. Here, we report the first Slovenian real-world experience with adjuvant nivolumab. Patients and methods. We conducted a retrospective, observational cohort study of patients with OEC/GEJC who received adjuvant nivolumab after neoCRT and radical resection between January 2022 and December 2023. Data on patient characteristics, treatment completion, disease progression, and immune-related adverse events (irAEs) were collected from medical records and analysed via descriptive statistics. Results. A total of 17 patients were included. The median follow-up was 34.6 months (range 11.2–55.7). The cohort included 14 (82%) males, with a mean age of 59 years. The Eastern Cooperative Oncology Group (ECOG) performance status was 0 for 15 (88%) patients and 1 for 2 (12%) patients. The tumor location was the esophagus in 9 (53%) patients and the gastroesophageal junction in 8 (47%) patients. At diagnosis, 13 (76%) patients were stage III (8th TNM classification). Histology revealed adenocarcinoma (AC) in 12 (71%) patients and squamous cell carcinoma (SCC) in 5 (29%) patients. Only 6 (35%) patients completed one year of adjuvant nivolumab. Treatment was discontinued in 5 (29%) patients due to disease progression and in 6 (35%) patients due to irAEs. Overall, 11 (65%) patients experienced irAEs of any grade. Grade 3 or 4 irAEs occurred in 4 (24%) patients: myocarditis G4 in 1 (6%) patient and colitis G3 in 3 (18%) patients. No irAE-related deaths were reported. The median disease-free survival (DFS) was 21.4 months (95% confidence interval CI, 14.6–28.9). Conclusions. Real-world data from Slovenia indicate that 65% of patients discontinued adjuvant nivolumab prematurely due to disease progression or irAEs. These findings highlight the need for careful patient selection and monitoring when using adjuvant immunotherapy in this population"},"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-VH7S9AL8","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-VH7S9AL8"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-VH7S9AL8/338c53bd-9af3-4fa0-bde0-868f802dcacd/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Društvo radiologije in onkologije"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-VH7S9AL8/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-VH7S9AL8"}}}}